Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data? Onvansertib combined with standard care showed up to 49% confirmed ORR in RAS-mutated colorectal cancer, with early signs of PFS benefit.
Which stocks are experiencing notable movement on Wednesday? Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
Let's have a look at the top gainers and losers in the middle of the day of today's session. Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Traders are paying attention to the gapping stocks in Wednesday's session. In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.
These stocks are moving in today's pre-market session As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Cardiff Oncology Shares Slide Over 26% In Premarket Trading After Mixed Q2 Cardiff Oncology Inc. (
NASDAQ: CRDF ) plummeted 22.96% in its stock value on Tuesday, following a disappointing second quarter earnings report.
What's going on in today's after hours session Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Top movers in Tuesday's after hours session Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.
US Small Business Optimism Hits 3-Year High As Election Results 'Signal A Major Shift' Small businesses are entering the holiday season with newfound confidence and momentum, thanks to post-election policies and reduced inflation.
What's Going On With Cardiff Oncology Stock On Tuesday? Cardiff Oncology's CRDF-004 trial shows promising onvansertib results in RAS-mutated mCRC patients, with higher tumor response rates and a strong safety profile.
CRDF Stock Earnings: Cardiff Oncology Misses EPS, Beats Revenue for Q2 2024 CRDF stock results show that Cardiff Oncology missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028 Finding good investing possibilities in the constantly changing stock market might be likened to unearthing buried jewels.
CRDF Stock Earnings: Cardiff Oncology Beats EPS, Beats Revenue for Q1 2024 CRDF stock results show that Cardiff Oncology beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
